

CURRICULUM VITAE

JEROME P. SCHARTMAN, MD

OFFICE ADDRESSES

Retina Associates of Cleveland, Inc.
690 White Pond Drive, Suite 120; Akron, Ohio 44320
3401 Enterprise Parkway, Suite 300; Beachwood, Ohio 44122
4690 Munson Street NW; Canton, Ohio 44718
340 Oxford Street, Suite 210; Dover, Ohio 44622
6100 South Broadway Avenue, Suite 200; Lorain, Ohio 44052
9485 Mentor Avenue, Suite 211; Mentor, Ohio 44060
15299 Bagley Road, Suite 200; Middleburg Heights, Ohio 44130
17534 Royalton Road, Suite 201; Strongsville, Ohio 44136
170 North Road NE; Warren, Ohio 44483
4350 Crocker Road, Suite 200; Westlake, Ohio 44145
5390 Belmont Avenue; Youngstown, Ohio 44505

TELEPHONE

216-831-5700

WEBSITE

www.retina-doctors.com

EDUCATION

College

Greensboro College
Greensboro, North Carolina
1990–1994, BA (summa cum laude, Music Performance and Liberal Arts)

Graduate School

Catholic University Graduate School of Music
Washington, DC
1995–1996, MM (Master's in Music)

Medical School

University of Maryland School of Medicine
Baltimore, Maryland
1999–2003, MD

POSTGRADUATE TRAINING

Internship

Internal Medicine
Christiana Care Medical Center
Wilmington, Delaware
2003–2004

Residency

Ophthalmology
Penn State Hershey Medical Center
Hershey, Pennsylvania
Veterans Affairs Hospital
Lebanon, Pennsylvania
2004–2007

Chief Resident
2006–2007

Fellowship

Vitreoretinal Diseases, Surgery and Uveitis Fellowship
Retina Consultants
Albany Medical Center and College of Medicine
Albany, New York
2007–2009

LICENSURE AND BOARD CERTIFICATION

Licensed to practice medicine in Ohio

Diplomate, American Board of Ophthalmology, 2009

PROFESSIONAL POSITIONS

Retina Associates of Cleveland, 2009–

Private practice in vitreoretinal surgery and diseases. Associates: Lawrence J. Singerman, MD; Michael A. Novak, MD; Hernando Zegarra, MD; Z. Nicholas Zakov, MD; Scott D. Pendergast, MD; David G. Miller, MD; Joseph M. Coney, MD; Llewelyn J. Rao, MD; Arnold F. Nothnagel, DO; Shawn A. Lewis, MD; Sean M. Platt, MD

Piano teacher and performer, private studio. Bethesda, Maryland, June 1994–June 1999

ACADEMIC APPOINTMENTS

Assistant Professor of Ophthalmology, Summa Health / Northeast Ohio Medical University, Akron City Hospital, 2010–

Assistant Professor of Ophthalmology, Albany Medical College, Albany, New York, 2007–2009

HONORS AND AWARDS

Patients' Choice Award, 2018

Best Doctors in America, 2015–2018

Belize Eye Mission, Belize City, Belize. Retina Research Foundation, Slingerlands, New York. October 2008

Resident Research Award, Penn State Department of Ophthalmology, June 2006

National Eye Institute Travel Grant Association for Research in Vision and Ophthalmology Annual Meeting, Ft. Lauderdale, Florida, May 2006

MEMBERSHIPS

American Academy of Ophthalmology, 2004–
American Society of Retinal Specialists, 2007–
Association for Research in Vision and Ophthalmology, 2006–

HOSPITAL & ASC AFFILIATIONS

Cleveland Eye and Laser Surgery Center, Cleveland, Ohio
Brainard Surgery Center; Cleveland, Ohio
Summa Health; Akron, Ohio

SCIENTIFIC REVIEWER POSITIONS

Journal of Ocular Pharmacology and Therapeutics, 2008–

Research grant scientific reviewer for Diabetes UK, The British Diabetic Association, London, England.

RESEARCH ACTIVITIES

NIH-funded Grants

DRCRnet Protocol W. Intravitreal anti-vascular endothelial growth factor treatment for prevention of vision threatening diabetic retinopathy in eyes at high risk

Co-investigator, 2017–

DRCRnet Protocol V. Treatment for central involved diabetic macular edema in eyes with very good visual acuity

Co-investigator, 2014–

DRCRnet Protocol U. Short-term evaluation of combination corticosteroid+anti-VEGF treatment for persistent central-involved diabetic macular edema following anti-VEGF therapy in pseudophakic eyes

Co-investigator, 2014–2017

Study of COmparative Treatments for REtinal Vein Occlusion 2 (SCORE2)

Co-investigator, 2014–

DRCRnet: Genes in diabetic retinopathy project

Co-investigator, 2012–

DRCRnet Protocol S. Prompt panretinal photocoagulation versus ranibizumab+deferred panretinal photocoagulation for proliferative diabetic retinopathy

Co-investigator, 2012–2017

DRCRnet Protocol M. Effect of diabetes education during retinal ophthalmology visits on diabetes control

Co-investigator, 2012–2015

DRCRnet Protocol R. Phase II evaluation of topical NSAIDs on eyes with non-central involved DME

Co-investigator, 2011–2013

Home vision monitoring in AREDS2 for progression to neovascular AMD using the ForeseeHome device

Co-investigator, 2011–2013

DRCRnet Protocol N. Evaluation of intravitreal ranibizumab for vitreous hemorrhage due to proliferative diabetic retinopathy

Co-investigator, 2010–2012

DRCRnet Protocol O. Comparison of time-domain OCT and spectral domain OCT retinal thickness measurement in diabetic macular edema

Co-investigator, 2009–2010

Other National Clinical Trials

Safety and efficacy study of gevokizumab to treat active non-infectious uveitis (EYEGUARD™-A)

Principal investigator, 2012–2015

Safety and efficacy study of gevokizumab to treat non-infectious uveitis controlled with systemic treatment (EYEGUARD™-C)

Principal investigator, 2012–2015

Multi-center, double-masked, parallel group, placebo-controlled study to assess the efficacy and safety of voclosporin as therapy in subjects with active noninfectious intermediate, posterior or pan-uveitis

Principal investigator, 2011–2013

Phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of RO6867461 in patients with diabetic macular edema (YOSEMITE)

Co-investigator, 2018–

Phase 2b randomized, double-masked, controlled trial to assess the safety and efficacy of intravitreal administration of Zimura™ (anti-c5 aptamer) in subjects with geographic atrophy secondary to dry age-related macular degeneration

Co-investigator, 2018–

Phase III randomised, double-masked, parallel group, multicentre study to compare the efficacy, safety, pharmacokinetics and immunogenicity between SB11 and Lucentis in subjects with neovascular age-related macular degeneration

Co-investigator, 2018–

Phase 2 double-masked, placebo-controlled study to assess the safety and efficacy of subcutaneously administered AKB-9778 15 mg once daily or 15 mg twice daily for 12 months in patients with moderate to severe non-proliferative diabetic retinopathy (TIME-2b study)

Co-investigator, 2017–

Phase III multicenter randomized, sham controlled, study to determine the safety and efficacy of Renexus® in macular telangiectasia type 2 (NTMT-03-A)

Co-investigator, 2017–

Efficacy and safety study of squalamine ophthalmic solution in subjects with neovascular AMD (MAKO)

Co-investigator, 2016–

Phase II, multicenter, randomized, single-masked, sham-controlled study of safety, tolerability and evidence of activity of intravitreal APL-2 therapy in patients with geographic atrophy (GA)

Co-investigator, 2015–2018

Phase III double masked study of safety and efficacy of abicipar pegol in patients with neovascular age-related macular degeneration

Co-investigator, 2015–

Randomized, double-masked, multicenter, three-arm study comparing the efficacy and safety of RTH258 versus aflibercept in subjects with neovascular age-related macular degeneration

Co-investigator, 2015–2018

Phase III, multicenter, randomized, double-masked, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patients with geographic atrophy secondary to age-related macular degeneration (PROXIMA)

Co-investigator, 2015–2018

Phase 3, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista (anti PDGF-B pegylated aptamer) administered in combination with either Avastin or Eylea compared to Avastin or Eylea monotherapy in subjects with subfoveal neovascular age-related macular degeneration

Co-investigator, 2015–2017

A study of larpalizumab intravitreal injections administered every two weeks or every four weeks to patients with geographic atrophy (EXPOSURE)

Co-investigator, 2015–2017

An 18-month Phase 2a open label, randomized study of Avastin, Lucentis, or Eylea (anti-VEGF therapy) administered in combination with Fovista (anti-PDGF BB pegylated aptamer)

Co-investigator, 2015–2017

LHA510 proof-of-concept study as a maintenance therapy for patients with wet age-related macular degeneration

Co-investigator, 2015–2016

A study investigating the efficacy and safety of larpalizumab intravitreal injections in patients with geographic atrophy secondary to age-related macular degeneration (CHROMA)

Co-investigator, 2014–2018

Phase 2, multi-center study to compare the efficacy and safety of a chemokine CCR2/5 receptor antagonist with ranibizumab in adults with diabetic macular edema

Co-investigator, 2014–2015

Phase 3, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal administration of Fovista (anti-PDGF-B pegylated aptamer) administered in combination with Lucentis compared to Lucentis monotherapy in subjects with subfoveal neovascular age-related macular degeneration

Co-investigator, 2013–2017

Phase 2b/3 multicenter, randomized, double-masked, dose-ranging study comparing the efficacy and safety of emixustat hydrochloride (ACU-4429) with placebo for the treatment of geographic atrophy associated with dry age-related macular degeneration (SEATTLE)

Co-investigator, 2013–2016

Prospective, two-cohort, single-masked study to evaluate the effect of ESBA1008 applied by microvolume injection or infusion in subjects with exudative age-related macular degeneration

Co-investigator, 2013–2015

Prospective, randomized, double-masked, multicenter, two-arm study comparing the efficacy and safety of ESBA1008 versus Eylea® in subjects with exudative age-related macular degeneration

Co-investigator, 2013–2014

Efficacy, safety and tolerability of cariprazine as an adjunctive treatment to antidepressant therapy (ADT) in patients with major depressive disorder (subcontractor for ophthalmological examinations)

Co-investigator, 2013–2014

Efficacy and safety of squalamine lactate eye drops in subjects with neovascular (wet) age-related macular degeneration

Co-investigator, 2012–2015

Intravitreal LFG316 in patients with age-related macular degeneration

Co-investigator, 2012–2015

Ocriplasmin for treatment for symptomatic vitreomacular adhesion including macular hole (OASIS)

Co-investigator, 2012–2014

Safety and tolerability of intravenous LFG316 in wet age-related macular degeneration

Co-investigator, 2012–2013

Single and repeat dose study of the safety and efficacy of AGN-150998 in patients with exudative age-related macular degeneration

Co-investigator, 2012

Phase 1 multicenter open-label safety and tolerability clinical trial of ciliary neurotrophic factor (CNTF) in patients with macular telangiectasia Type 2

Co-investigator, 2011–2016

A study of safety, tolerability, and evidence of activity of FCFD4514S administered monthly or every other month to patients with geographic atrophy

Co-investigator, 2011–2013

Multicenter, 2 stage (open label, dose escalation, followed by masked, randomized) single dose study of the safety and efficacy of AGN-208397 in patients with macular edema (ME) associated with retinal vein occlusion (RVO)

Co-investigator, 2011–2012

Phase 2b dose-ranging study of pazopanib eye drops versus ranibizumab intravitreal injections for the treatment of neovascular age-related macular degeneration

Co-investigator, 2010–2011

Phase 2, randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreal injections of E10030 (anti-PDGF pegylated aptamer) given in combination with Lucentis® in subjects with neovascular age-related macular degeneration

Co-investigator, 2010–2011

A natural history and registry study of macular telangiectasia specifically studying the group 2 macular telangiectasia

Co-investigator, 2009–

Impact of Lucentis on psychological morbidity in patients with macular edema and neovascularization secondary to retinal vein occlusion

Co-investigator, 2009–2012

Phase III, double-masked, multicenter, randomized, active treatment-controlled study of the efficacy and safety of 0.5 mg and 2.0 mg ranibizumab administered monthly or on an as-needed basis (PRN) in patients with subfoveal neovascular age-related macular degeneration (HARBOR)

Co-investigator, 2009–2012

Phase II, randomized, double-masked, placebo-controlled, add-on study to assess the efficacy of oral aliskiren 300 mg one daily for diabetic macular edema

Co-investigator, 2009–2010

VIEW 1: Phase III randomized multicenter clinical trial of a novel intravitreal treatment for age-related macular degeneration (VEGF-Trap)

Co-investigator, 2009

A study of ranibizumab injection in subjects with clinically significant with macular edema center involvement secondary to diabetes mellitus (RIDE)

Co-investigator, 2009

Other Research Activities

Uniformed Services University of the Health Sciences, Bethesda, Maryland

Department of Pathology and Immunology; Head investigator, Clifford M Snapper, MD

- Research intern, June 1998–June 1999

SELECTED PRESENTATIONS AT MEETINGS AND SYMPOSIA

Co-moderator, Inflammatory Eye Disease Symposium. Cleveland Ophthalmological Society Meeting. Cleveland, Ohio, December 11, 2018.

Vitrectomy for symptomatic vitreous floaters. Optometric Retinal Update. Beachwood, Ohio, February 15, 2017. Cleveland Ophthalmological Society. Cleveland, Ohio, April 10, 2018.

Vitrectomy for symptomatic vitreous floaters. Optometric Retinal Update. Beachwood, Ohio, February 15, 2017.

Age-related macular degeneration and other retinal diseases. Lorain County Community Health Fair. Lorain, Ohio, September 30, 2017.

Uveitis...or is it? Community Doctors Education Program. Cleveland, Ohio, June 8, 2017

Retinal emergencies. Cleveland Ophthalmic Personnel Society Meeting. Independence, Ohio, April 4, 2017.

Unusual retinal cases. Optometric Retinal Update. Beachwood, Ohio, March 28, 2017.

The MacTel (Macular Telangiectasia) Project. Optometric Retinal Update. Beachwood, Ohio, February 18, 2016.

Update on OCT for Retinal Disease. Optometric Retinal Update. Cleveland, Ohio, June 18, 2015.

Diabetes and cataract surgery. Cleveland Ophthalmological Society Diabetes Symposium. Cleveland, Ohio, October 14, 2014.

Update on surgical outcomes 2014. Optometric Retinal Update. Cleveland, Ohio, June 26, 2014.

Update on surgical outcomes 2014. Optometric Retinal Update. Beachwood, Ohio, March 20, 2014.

Polypoidal choroidal vasculopathy. Cleveland Ophthalmological Society. Cleveland, Ohio, October 15, 2013.

Choroidal neovascularization. Optometric Retinal Update. Beachwood, Ohio, March 14, 2013.

Retinal update on anti-VEGF therapy (with Drs. Coney, Miller, Novak, Rao, and Zegarra). Ophthalmologists' Update Seminar. Vermilion, Ohio, December 20, 2012.

Retinal update on anti-VEGF therapy (with Drs. Coney, Miller, Novak, Rao, and Zegarra). Ophthalmologists' Update Seminar. Vermilion, Ohio, August 12, 2012.

Interesting retinal cases: clinical assessment and management. Optometric Retinal Update. Westlake, Ohio, June 5, 2012.

Exudative retinal detachment in ocular inflammation and uveitis. Cleveland Ophthalmological Society. Cleveland, Ohio, February 14, 2012.

Latest technology for age-related macular degeneration (AMD). Patient Seminar on AMD. Corporate College, Warrensville Heights, Ohio, July 23, 2011.

Uveitis: evaluation and management. Optometric Retinal Update. Westlake, Ohio, June 28, 2011.

Latest technology in treating macular degeneration. Foundation Fighting Blindness seminar. Eastlake, Ohio, April 13, 2011.

Serous retinopathy. Optometric Retinal Update Seminar. Beachwood, Ohio, March 3, 2011.

Retinal imaging. Cleveland Eye Clinic Update on Macular Degeneration, OCT Imaging, and Retinal Disease. Cleveland, Ohio, January 26, 2011.

Case report: central serous retinopathy with total retinal detachment. Cleveland Ophthalmological Society. Cleveland, Ohio, October 12, 2010.

Update on retinal surgery. Optometric Retinal Update. Westlake, Ohio, August 19, 2010.

Interesting retinal cases. Optometric Retinal Update Seminar. Beachwood, Ohio, March 25, 2010.

New technology in the treatment of retinal degenerations. Keynote address, Regional Conference of the Association for Education and Rehabilitation of the Blind and Visually Impaired. Cleveland, Ohio, November 13, 2009.

Interesting retinal cases: clinical assessment and management. Optometric Retinal Update. Youngstown, Ohio, August 20, 2009.

Technology in age-related macular degeneration. Presentation for patients in association with Retina Associates of Cleveland. Beachwood, Ohio, April 2009.

Lectures for core residency education. Albany Medical Center, Albany, New York, July 2009.

Macular and retinal diseases. Lectures for core physician assistant education. Albany Medical Center. Albany, New York, January 2009.

Complications of intravitreal steroids. Grand Rounds Lecture, Ross Eye Institute. Buffalo, New York, December 2008.

Surgical treatment of central serous chorioretinopathy complicated by total retinal detachment (with PM Beer, MF Giganti, NS Falk). Wills Eye Lecture, Wills Eye Annual Retina Conference. Philadelphia, Pennsylvania, October 2008

Fundus and fluorescein angiography. Lectures for core residency education. Conferences. Albany Medical Center. Albany, New York, 2007–2008.

Update in retinal diseases. Lecture for technicians and office support staff. New York State Ophthalmology Society Annual Meeting. Albany, New York, October 2007.

How to manage vision loss in retinitis pigmentosa. Central Pennsylvania Retina Society Annual Meeting, June 2006.

Five unusual cases: a day at the office. Penn State Ophthalmology Annual Technician Education Meeting. Hershey, Pennsylvania, January 2007.

Outcomes following treatment of post-surgical or post-traumatic cyclodialysis cleft: retrospective review (with A Aminlari). Penn State College of Medicine Annual Research Day, June 2006.

Optical coherence tomography compared with biomicroscopy in detecting abnormalities of the macula in patients following repair of rhegmatogenous retinal detachment (with K Neely). Penn State College of Medicine Annual Research Day. Hershey, Pennsylvania, June 2005.

Atypical central serous chorioretinopathy in the setting of systemic lupus erythematosus. Penn State Ophthalmology Annual Alumni Day. Hershey, Pennsylvania, September 2005.

Retinal degeneration in membranoproliferative glomerulonephropathy type II. Central Pennsylvania Retina Society Annual Meeting. Hershey, Pennsylvania, May 2005.

Ocular anatomy and the red eye. Penn State Ophthalmology Technician Lecture Series. Hershey, Pennsylvania, February 2005

Ocular siderosis secondary to chronic occult intraocular foreign body. Penn State Ophthalmology Annual Alumni Day. Hershey, Pennsylvania, September 2004.

PUBLICATIONS

Journal articles

1. Chew EY, Clemons TE, Jaffe GJ, Johnson CA, Farsiu S, Lad EM, Guymer R, Rosenfeld P, Hubschman JP, Constable I, Wiley H, Singerman LJ, Gillies M, Comer G, Blodi B, Elliott D, Yan J, Bird A, Friedlander M; Macular Telangiectasia Type 2-Phase 2 CNTF Research Group. Effect of ciliary neurotrophic factor on retinal neurodegeneration in patients with macular telangiectasia type 2: a randomized clinical trial. *Ophthalmology*. 2018 Oct 4. pii: S0161-6420(18)31427-1. doi: 10.1016/j.ophtha.2018.09.041. [Epub ahead of print]
2. Jampol LM, Glassman AR, Liu D, Aiello LP, Bressler NM, Duh EJ, Quaggin S, Wells JA, Wykoff CC; Diabetic Retinopathy Clinical Research Network. Plasma vascular endothelial growth factor concentrations after intravitreal anti-vascular endothelial growth factor therapy for diabetic macular edema. *Ophthalmology*. 2018;125:1054-1063.
3. Bressler SB, Ayala AR, Bressler NM, Melia M, Qin H, Ferris FL 3rd, Flaxel CJ, Friedman SM, Glassman AR, Jampol LM, Rauser ME; Diabetic Retinopathy Clinical Research Network. Persistent macular thickening after ranibizumab treatment. *JAMA Ophthalmol*. 2016 Mar 1;134:278-285.
4. Wells JA, Glassman AR, Jampol LM, Aiello LP, Antoszyk AN, Baker CW, Bressler NM, Browning DJ, Connor CG, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW; Diabetic Retinopathy Clinical Research Network. Association of baseline visual acuity and retinal thickness with 1-year efficacy of aflibercept, bevacizumab, and ranibizumab for diabetic macular edema. *JAMA Ophthalmol*. 2016;134:127-134.
5. Writing Committee for the Diabetic Retinopathy Clinical Research Network, Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, Baker CW, Berger BB, Bressler NM, Browning D, Elman MJ, Ferris FL 3rd, Friedman SM, Marcus DM, Melia M, Stockdale CR, Sun JK, Beck RW. Panretinal photocoagulation vs intravitreal

- ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. *JAMA*. 2015 Nov 13:1-11.
6. Aiello LP, Ayala AR, Antoszyk AN, Arnold-Bush B, Baker C, Bressler NM, Elman MJ, Glassman AR, Jampol LM, Melia M, Nielsen J, Wolpert HA; Diabetic Retinopathy Clinical Research Network. Assessing the effect of personalized diabetes risk assessments during ophthalmologic visits on glycemic control: a randomized clinical trial. *JAMA Ophthalmol*. 2015;133:888-896.
 7. Bressler SB, Almkhatar T, Bhorade A, Bressler NM, Glassman AR, Huang SS, Jampol LM, Kim JE, Melia M; Diabetic Retinopathy Clinical Research Network Investigators. Repeated intravitreal ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. *JAMA Ophthalmol* 2015;133:589-597.
 8. Diabetic Retinopathy Clinical Research Network, Wells JA, Glassman AR, Ayala AR, Jampol LM, Aiello LP, Antoszyk AN, Arnold-Bush B, Baker CW, Bressler NM, Browning DJ, Elman MJ, Ferris FL, Friedman SM, Melia M, Pieramici DJ, Sun JK, Beck RW. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. *N Engl J Med* 2015 Mar 26;372:1193-1203.
 9. Chew EY, Clemons TE, Peto T, Sallo FB, Ingerman A, Tao W, Singerman L, Schwartz SD, Peachey NS, Bird AC; MacTel-CNTF Research Group. Ciliary neurotrophic factor (CNTF) for macular telangiectasia Type 2 (MacTel): Results from a phase I safety trial. *Am J Ophthalmol* 2015;159:659-666.
 10. Rao LJ, Coney JM, Schartman JP, Singerman, LJ. Neovascular AMD: treatment beyond anti-VEGF. *Physician* 2014;11:23-28.
 11. Diabetic Retinopathy Clinical Research Network. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. *JAMA Ophthalmol* 2013;131:283-293.
 12. Diabetic Retinopathy Clinical Research Network, Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, Ferris FL 3rd, Glassman AR, Maturi RK, Melia M. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. *Ophthalmology* 2012;119:2312-2318.
 13. Schartman JP, Coney JM, Miller DG. Pegaptanib octasodium for the treatment of diabetic macular oedema. *Expert Opinion on Pharmacotherapy* 2011;12:1317-1323.
 14. Gangaputra S, Almkhatar T, Glassman AR, Aiello LP, Bressler N, Bressler SB, Danis RP, Davis MD; Diabetic Retinopathy Clinical Research Network. Comparison of film and digital fundus photographs in eyes of individuals with diabetes mellitus. *Invest Ophthalmol Vis Sci* 2011;52:6168-6173.

15. Coney JM, Schartman JP, Singerman LJ. Advancing treatments for diabetic macular edema. *Retinal Physician* 2011;8:40, 43-44, 46.
16. Flaxel CJ, Edwards AR, Aiello LP, Arrigg PG, Beck RW, Bressler NM, Bressler SB, Ferris FL 3rd, Gupta SK, Haller JA, Lazarus HS, Qin H. Factors associated with visual acuity outcomes after vitrectomy for diabetic macular edema: Diabetic Retinopathy Clinical Research Network. *Retina* 2010;30:1488-1495.
17. Beer PM, Wong S, Schartman JP, Kulas K, Hartman CL, Giganti MF, Falk NS. Infliximab stability after reconstitution, dilution, and storage under refrigeration. *Retina* 2010;30:81-84.
18. Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N. Adverse events after intravitreal infliximab (Remicade). *Retina* 2010;30:71-80.
19. Schartman JP, Beer PM, Giganti MF, Falk NS. Surgical treatment of central serous chorioretinopathy complicated by total exudative retinal detachment. *Retinal Cases and Brief Reports*. In press.
20. Schartman JP, Beer PM, Falk NS. Anti-VEGF therapy for age-related macular degeneration. *Contemp Ophthalmol* 2008;7:1-8
21. Schartman JP, Scott IU. How to manage vision loss in retinitis pigmentosa. *Eye-net: Ophthalmic Pearls* 2006;10:29-31.
22. Schartman JP, Weinstein J. Re: Intermittent disconjugate gaze: a novel finding in nonalcoholic steatohepatitis. *Hepatology* 2006;43:882-883 (Letter).
23. Wu ZQ, Khan AQ, Shen Y, Schartman JP, Peach R, Lees A, Mond JJ, Gause WC, Snapper CM. B7 requirements for primary and secondary protein- and polysaccharide-specific Ig isotype responses to *Streptococcus pneumoniae*. *J Immunol* 15 Dec 2000;165:6840-6848.

Posters

1. Liu J, Coney J, Schartman J, Miller DG, Zegarra H, Rao L. Fluocinolone acetonide (FAc) 0.2 mg intravitreal implant in the treatment of diabetic macular edema (DME).
 - Poster 4816 - C0174, Association for Research in Vision and Ophthalmology Annual Meeting. Honolulu, Hawaii, May 2018.
 - Best PGY-3 Resident VSRC Research Presentation, University Hospitals Ophthalmology Residents Research Day Symposium, June 2018
2. Singerman LJ, Himmelman DR, Singerman B, Thomas A, Newman L, Coney JM, Schartman JP, Novak MA. Impact of Lucentis on psychological morbidity in patients with macular edema and neovascularization secondary to retinal vein occlusion.

- Program#/Poster# 5466/A662. Association for Research in Vision and Ophthalmology Annual Meeting. Fort Lauderdale, Florida, May 2012.
3. Lemanski N, Schartman JP, Beer PM, Falk NS, Hartman CL. SALVAGE Study (NCT00467935): Intravitreal ranibizumab for treatment of advanced macular dysfunction in patients with disciform fibrosis due to exudative AMD. Scientific Poster 246, American Academy of Ophthalmology Annual Meeting. San Francisco, California, October 23–27, 2009.
 4. Schartman JP, Beer PM, Giganti MF, Falk NS. Surgical treatment of central serous chorioretinopathy complicated by total retinal detachment. Retina Congress: combined meeting of the American Society of Retina Specialists, the Macula Society, and the Retina Society. New York, NY, September-October 2009.
 5. Beer PM, Schartman JP, Falk NS. Intravitreal infliximab for retinal diseases: preliminary report of a phase one clinical trial. American Society of Retina Specialists (ASRS) Annual Meeting. Maui, Hawaii, October 2008.
 6. Lemanski N, Schartman JP, Falk NS, Hartman C, Beer PM. Intravitreal ranibizumab for the treatment of disciform age-related macular degeneration: the SALVAGE study. American Society of Retina Specialists (ASRS) Annual Meeting. Maui, Hawaii, October 2008.
 7. Gloth J, Falk NS, Schartman JP, Beer PM. Incidence of adverse effects with intravitreal triamcinolone: 20 mg versus 4 mg. American Society of Retina Specialists (ASRS) Annual Meeting. Maui, Hawaii, October 2008.
 8. Lemanski N, Schartman JP, Falk NS, Hartman C, Beer PM. Intravitreal ranibizumab for the treatment of disciform age-related macular degeneration: the SALVAGE study, Interim results. Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. Fort Lauderdale, Florida, April 2008.
 9. Schartman JP, Scott IU, Gardner TW. Outcomes of pneumatic retinopexy versus scleral buckling for rhegmatogenous retinal detachment repair in patients with good presenting visual acuity. Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. Fort Lauderdale, Florida, May 2007.
 10. Schartman JP, Quillen DA, Passantino K, Antonetti D, Gardner TW. Prevalence of cystoid macular edema in patients with diabetic clinically significant macular edema. Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. Fort Lauderdale, Florida, May 2006.